NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
- Funder
- National Institutes of Health
- Award amount
- Not specified
- Deadline
- May 8, 2028
- Eligible countries
- United States
Summary
This Notice of Funding Opportunity (NOFO) invites applications to use NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders. No funding will be provided under this NOFO. The genomic data and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBIs BioData Catalyst (BDC). The overall goal is to move from simply cataloguing genetic associations to understanding how genetic factors contribute to HLBS diseases at the molecular and cellular levels. This transformation will help move TOPMed from genetic Map to Mechanism with potential applications of AI and ML tool sets where possible, enabling functional genomics research that will accelerate mechanistic personalized medicine
Summary as listed on Grants.gov (opportunity 359942). Always read the full announcement for eligibility, limits and how to apply.
Read the full announcement on Grants.gov →What National Institutes of Health reviewers look for
- Importance of the research (significance and innovation), scored 1–9.
- Rigor and feasibility of the approach, scored 1–9. Preliminary data and alternative strategies carry much of this.
- Expertise and resources, rated sufficient or not, without a score.
- Overall impact: the likelihood the project will have a sustained, powerful influence on its field.
Read our guide: what funded applications do →
See how this call matches your research
Build a free research profile and GrantMatch scores every open call against your work, tracks your deadlines and reminds you before they pass.
Get matched free